Bolivia Medical Device Registration: Manufacturer Representation Filing without Consular Legalisation

1. Key takeaways

Section 2.3.4 of the manual provides that the manufacturer representation document is not resubmitted with each dossier. Instead it is filed in advance, in original, with the AGEMED vigilance and control area (área de Vigilancia y Control), and it does not require consular legalisation. This mirrors Article 42 of Decreto Supremo N° 25235 (30 November 1998), which requires the importing enterprise to register with the Ministry of Health the legal representation conferred on it by the manufacturing plant, stating its period of validity. GRZAN’s warning is that this is a filing independent of any individual product registration: if it has not been completed in advance, the first submission will be treated as incomplete.

The structure of the requirement carries a practical implication that is easy to miss at the start of a project. Because the document is filed once and then referred to, it behaves like an infrastructure item rather than like a dossier component: it is invisible when it is in place, and it stops everything when it is not. Projects that plan the technical file before the representation filing routinely lose weeks to a step that could have been completed while the technical documentation was still being drafted.

The filing also has a second function that the manual does not spell out in section 2.3.4 but that follows from where the document is lodged. A filing held by the vigilance and control area is a channel as well as a record, and a channel is only useful while the contact details in it remain accurate.

2. Legal basis

The manual and the decree address the same instrument from different directions. Section 2.3.4 fixes the procedural route: original document, filed in advance, lodged with the vigilance and control area, no consular legalisation. Article 42 fixes the substantive content and adds the requirement that the period of validity be stated. Section 2.2.3 sets out the signature page that carries the grantor, the grantee, the product rights holder, the manufacturer and every site where the product is manufactured, filled or packed, while section 2.3.2 governs the certificate of free sale and imposes a different authentication requirement on it. The four provisions must be read together because they impose different obligations on documents that travel in the same file.

3. Expert insights

Insight 1: filing in advance rather than per dossier is a significant efficiency design. A single filing can support every subsequent product registration held by that enterprise. For the manufacturer this reduces duplicated cost and duplicated authentication effort across a portfolio. It also concentrates risk in one place: an expired representation document affects every product registered under it, which places it in the same category of exposure as the lapse of an enterprise qualification discussed in article 22 of this series.

Insight 2: the exemption from consular legalisation contrasts with the certificate of free sale requirement. Section 2.3.4 states that the representation document does not require consular legalisation, while section 2.3.2 requires the certificate of free sale to be issued or endorsed and then legalised. Two categories of document in the same dossier carry different authentication requirements, so a single uniform authentication plan will either over-process the representation document or under-process the certificate of free sale. The requirements must be applied document by document, and the plan should record which rule applies to which certificate.

Insight 3: the filing destination points to a second function. The representation document is lodged with the vigilance and control area, which indicates that it also serves as the contact basis for technical vigilance responsibility: AGEMED reaches the manufacturer’s representative through this route. The contact information in the document therefore has to remain valid for as long as the registration exists, not merely at the date of filing, and a defunct email address in a representation filing is a compliance problem rather than an administrative inconvenience.

Insight 4: the filing is a milestone that should precede technical work, not follow it. Sequencing the filing ahead of dossier preparation costs nothing and removes a dependency that otherwise surfaces at the worst possible moment. GRZAN’s practice is to treat the representation filing as the first milestone of a Bolivian project, with the technical file scheduled behind it rather than beside it.

4. Practical recommendations

1. Make the representation filing the first milestone of the project, scheduled ahead of dossier preparation rather than after it.
2. State a defined period of validity in the document, and set a reminder before expiry, with three months of lead time as a practical estimate.
3. Ensure that the contact information remains valid over the long term, and name an individual who can receive technical vigilance communications.
4. Keep a copy of the filed original and the date of lodgement on file, so that completeness can be demonstrated in any later submission or inspection.

5. Verification checklist

• □ The representation document has been filed in original with the AGEMED vigilance and control area
• □ The document states a defined period of validity
• □ Confirmation has been obtained that the document does not require consular legalisation
• □ The filing precedes the first product dossier submission
• □ The contact information in the document is a long-term channel

Regulatory information verified as of October 29, 2026.

GRZAN supports medical device manufacturers, importers and authorised representatives with registration in Bolivia, including advance filing of manufacturer representation documents under section 2.3.4 of Resolución Ministerial N° 010 and Article 42 of Decreto Supremo N° 25235, the drafting of the representation instrument with a defined validity period, and the maintenance of vigilance contact channels over the life of a registration. For assistance with a representation filing or a dossier sequence in Bolivia, contact the GRZAN regulatory team at info@grzanglobal.com.

GRZAN applies a writing standard of conclusions first, traceable sources and verifiable figures to its regulatory publications, and follows the practice of AGEMED and the other authorities cited in this series as it develops. For a market access plan that sequences the representation filing, the dossier and the import chain correctly for Bolivia, the team welcomes your enquiry.